Related News
-
Prometheus Launches the First…
Wednesday, September 1, 2010
SAN DIEGO -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the… more...
-
Banana Plantain Fibers Could…
Thursday, August 26, 2010
Crohn's is a condition that affects one in 800 people in the UK and causes chronic intestinal inflammation, leading to… more...
-
Pentasa(R) - Shire Receives…
Wednesday, August 25, 2010
DUBLIN and PHILADELPHIA -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,… more...
-
Studies Offer Encouraging…
Friday, August 6, 2010
Biological agents may play an important role in maintaining remission in Crohn's disease, according to two new studies… more...
-
Amid the Murk of 'Gut Flora…
Monday, July 12, 2010
Within the human digestive tract is a teeming mass of hundreds of types of bacteria, a potpourri of microbes numbering… more...
News
-
CheckOrphan NewsFlash April 30,…
4/30/2010
CheckOrphan NewsFlash for Tuesday, March 30, 2010: breaking news about rare diseases, orphan diseases, orphan drugs,…
-
CheckOrphan NewsFlash April 9,…
4/09/2010
CheckOrphan NewsFlash for Friday, April 9, 2010: breaking news about rare diseases, orphan diseases, orphan drugs, and…
-
CheckOrphan NewsFlash April 1,…
4/01/2010
CheckOrphan NewsFlash for Thursday, April 1, 2010: breaking news about rare diseases, orphan diseases, orphan drugs,…
NewsFlash
More News
-
Results From Investigator-Sponsored…
NOVATO, Calif. -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that… more...
-
Celldex Therapeutics Regains Worldwide…
NEEDHAM, Mass. -- Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced today it will… more...
-
Merck Serono's Cladribine Tablets for…
GENEVA, Switzerland -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany,… more...
-
Santhera and Ipsen Enter Into Licensing…
Liestal, Switzerland and Paris, France -- Santhera Pharmaceuticals (SIX: SANN) and Ipsen… more...
-
Celator Pharmaceuticals Raises $20…
Princeton, NJ -- Celator Pharmaceuticals, a privately held pharmaceutical company… more...
Treatment News
Distinct Demographic Profiles Between Crohn's Disease and Ulcerative Colitis
| More
Monday, February 8, 2010
Although inflammatory bowel disease (IBD) [comprising mainly Crohn's disease (CD) and ulcerative colitis (UC)] is thought to affect about 150 000 people in the United Kingdom, the prevalence of severe IBD is not known.
Mortality following hospitalization for IBD is significant but little has been reported on long-term follow-up.
A research article to be published on January 28, 2010 in the World Journal of Gastroenterology addresses this question. The research team from United Kingdom determined the hospitalized prevalence of severe IBD and subsequent 5-year mortality in Wales, and investigated associations between severe IBD and social deprivation, distance travelled to hospital, and other socio-demographic characteristics.
They found that hospitalization for severe CD was more common among women than men and it peaked among younger people aged 16-29 years. UC was similar among men and women and was more common among older people. There was no link between social deprivation and UC, but CD was more common among more deprived social groups.
The differing demographic profiles between CD and UC, suggest that environmental factors play a more significant role in the etiology of CD. The findings of this large population-based study on the prevalence and mortality of IBD are also important for service planning and provision.
***
Reference: Button LA, Roberts SE, Goldacre MJ, Akbari A, Rodgers SE, Williams JG. Hospitalized prevalence and 5-year mortality for IBD: Record linkage study. World J Gastroenterol 2010; 16(4): 431-438 (http://www.wjgnet.com/1007-9327/16/431.asp)
Correspondence to: Dr. Stephen E Roberts, School of Medicine, Swansea University, Singleton Park, Swansea, SA2 8PP, United Kingdom. stephen.e.roberts@swansea.ac.uk
Telephone: +44-1792-513426 Fax: +44-1792-513423
About World Journal of Gastroenterology
World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H. pylori infection and provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2008 IF: 2.081. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.
Contact: Ye-Ru Wang wjg@wjgnet.com 86-105-908-0039
Source: World Journal of Gastroenterology
Log in to comment.